Formulation and Evaluation of Sildenafil Citrate-Fluoxetine Hydrochloride Capsules with Derivative Spectrophotometric Analysis
International Journal of Drug Delivery Technology · 04.04.2026 · 16 (89s)
DOI: 10.25258/ijddt.16.89s.50 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 04.04.2026. Verfasst von Patel Akash Bhavdeepbhai und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Formulation development involves evaluating Preformulation characteristics, powder flow, excipient compatibility, dosage-unit quality, and drug-release behaviour. Reliable analytical methods are essential for the quantitative determination of active pharmaceutical ingredients.
Objective
To prepare and evaluate four capsule formulations containing sildenafil citrate and fluoxetine hydrochloride and summarize the performance of a derivative spectrophotometric method for their analysis.
Methods
Four formulations (F1-F4) were prepared using microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. The recorded evaluations included physicochemical characteristics, powder-flow indices, FTIR, UV and derivative spectrophotometry, capsule quality attributes, in vitro dissolution, moisture uptake, capsule-lock integrity, and stability observations.
Results
The melting points of sildenafil citrate and fluoxetine hydrochloride were 188.2 ± 0.5°C and 159.1 ± 0.4°C, respectively. Carr’s index ranged from 13.54% to 13.93%. Formulation F4 showed a disintegration time of 6.25 ± 0.10 min, moisture content of 2.21 ± 0.03%, and moisture uptake of 0.96 ± 0.02%. Sildenafil citrate release from F1-F4 at 30 min was 90.7%, 94.8%, 98.1%, and 100.0%, respectively. Fluoxetine hydrochloride release at 24 h was 90.23%, 92.45%, 91.63%, and 100.00%, respectively. The F4 assay values were 100.2% for sildenafil citrate and 100.0% for fluoxetine hydrochloride.
Conclusion
Formulation F4 demonstrated the most favourable capsule-quality and in vitro release results. However, inconsistencies in the source data, including calibration equations, LOD/LOQ assignments, precision-table labels, and selected statistics, must be resolved using the original laboratory records before definitive analytical validation claims can be made. Keywords: Sildenafil Citrate; Fluoxetine Hydrochloride; Capsules; Preformulation; Derivative Spectrophotometry; FTIR; Dissolution; Formulation Evaluation.
Zitieren
APA
Bhavdeepbhai, P. A., Patel, U., Bhimani, B. V., & Trivedi, H. J. (2026). Formulation and Evaluation of Sildenafil Citrate-Fluoxetine Hydrochloride Capsules with Derivative Spectrophotometric Analysis. International Journal of Drug Delivery Technology, 16(89s). https://doi.org/10.25258/ijddt.16.89s.50
Vancouver
Bhavdeepbhai PA, Patel U, Bhimani BV, Trivedi HJ. Formulation and Evaluation of Sildenafil Citrate-Fluoxetine Hydrochloride Capsules with Derivative Spectrophotometric Analysis. International Journal of Drug Delivery Technology. 2026;16(89s). doi:10.25258/ijddt.16.89s.50
BibTeX
@article{Bhavdeepbhai2026,
author = {Bhavdeepbhai, Patel Akash and Patel, Upendra and Bhimani, Bhavin Vasantray and Trivedi, Harsh Jitendrabhai},
title = {Formulation and Evaluation of Sildenafil Citrate-Fluoxetine Hydrochloride Capsules with Derivative Spectrophotometric Analysis},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {89s},
doi = {10.25258/ijddt.16.89s.50}
}
EUVIMED